Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deaths from variant Creutzfeldt-Jakob disease in the UK.
Andrews NJ, Farrington CP, Ward HJ, Cousens SN, Smith PG, Molesworth AM, Knight RS, Ironside JW, Will RG. Andrews NJ, et al. Lancet. 2003 Mar 1;361(9359):751-2. doi: 10.1016/s0140-6736(03)12632-3. Lancet. 2003. PMID: 12620741
Diphtheria immunity in UK blood donors.
Maple PA, Efstratiou A, George RC, Andrews NJ, Sesardic D. Maple PA, et al. Among authors: andrews nj. Lancet. 1995 Apr 15;345(8955):963-5. doi: 10.1016/s0140-6736(95)90705-x. Lancet. 1995. PMID: 7715300
Incidence of variant Creutzfeldt-Jakob disease in the UK.
Andrews NJ, Farrington CP, Cousens SN, Smith PG, Ward H, Knight RS, Ironside JW, Will RG. Andrews NJ, et al. Lancet. 2000 Aug 5;356(9228):481-2. doi: 10.1016/s0140-6736(00)02559-9. Lancet. 2000. PMID: 10981894
Idiopathic thrombocytopenic purpura and MMR vaccine.
Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Miller E, et al. Arch Dis Child. 2001 Mar;84(3):227-9. doi: 10.1136/adc.84.3.227. Arch Dis Child. 2001. PMID: 11207170 Free PMC article.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, England A, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Horsington BM, Lambe T, Lazarus R, Libri V, Lillie PJ, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, White R, Nguyen-Van-Tam JS, Snape MD; Com-COV2 Study Group. Stuart ASV, et al. Among authors: andrews nj. Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6. Lancet. 2022. PMID: 34883053 Free PMC article. Clinical Trial.
229 results